secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001517022-24-000007
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Akebia Therapeutics appoints Richard Malabre as Chief Accounting Officer
------------------------------------------------------------------------

- Richard C. Malabre named CAO effective January 8, 2024, reporting to CFO Ellen Snow.
- Base salary of $380,000; annual cash bonus target up to 35% of base salary.
- Granted options for 336,000 shares (4-year vest) and RSUs for 223,950 shares (3-year vest).
- Malabre previously CFO of Ultivue, Inc. and VP/Corporate Controller at Oxford Immunotec.
- Company will enter into standard Indemnification and Executive Severance Agreements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000007/0001517022-24-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000007/akba-20240108.htm
  HTML page:      https://secwatch.observer/filing/0001517022-24-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer